TOPLINE

Loncastuximab tesirine demonstrated clinical activity in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including responses in those previously treated with chimeric antigen receptor (CAR) T‑cell therapy.

METHODOLOGY

• Researchers conducted a systematic review and meta-analysis of studies evaluating loncastuximab tesirine in patients with relapsed/refractory DLBCL, including those treated after CAR T‑cell therapy.
• They included 7 studies from multiple databases through October 2025. The analysis involved 596 patients from multiple clinical trials and real-world studies.
• Patients had received multiple prior lines of therapy, and analyses compared outcomes with up to three prior lines and those with more than three.
• The endpoints included overall response rate (ORR) and complete response (CR) rate, progression-free survival, overall survival, and safety outcomes.
• A subgroup analysis examined outcomes specifically in 290 patients who had received prior CAR T-cell therapy.

TAKEAWAY

• The pooled ORR was 45.76% (heterogeneity [I²] = 94.3%); the CR rate was 18.83% (I² = 85.5%) across five studies. The pooled ORR was 43.45% among those who received three or fewer prior lines of therapy, and 50.27% among those who received more than three lines of therapy.
• The pooled ORR was 44.51% among patients who had previously received CAR T-cell therapy (5 studies) and 39.79% among those without prior CAR T-cell therapy.
• Across four studies, pooled median progression-free survival was 5.18 months, and pooled median overall survival was 9.01 months.
• The main adverse events were grade ≥ 3 cytopenias, fluid‑related events, and treatment discontinuation for adverse events in 12.6% of patients.

IN PRACTICE

"Across clinical trials and real‐world cohorts, loncastuximab tesirine showed clinically meaningful activity in heavily pretreated R/R [relapsed/refractory] LBCL, including CAR T‐cell therapy-exposed populations, with durable benefit in a subset of complete responders," the authors of the study wrote.

SOURCE

The study was led by Fernando Gibran-Nunes, MD, Advanced Therapies and Clinical Research Center, Hospital Sírio-Libanês in São Paulo, Brazil. It was published online on July 22 in Cancer.

LIMITATIONS

The study had substantial heterogeneity for key binary endpoints. Most included studies were single‑arm or retrospective, preventing direct comparisons. Time‑to‑event outcomes used reconstructed patient data from published curves and were approximate.

DISCLOSURES

The article did not report a source of funding. One author reported receiving fees for professional activities from pharmaceutical companies.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.